An oral presentation at this year’s European Society of Medical Oncology (ESMO) congress has provided an insight into the impact of stopping treatment with a checkpoint inhibitor at one year, versus continuing treatment.
The data from the CheckMate153 trial of Opdivo (nivolumab), treating certain non-small cell lung cancer patients, were presented by New York’s Bristol-Myers Squibb (NYSE: BMS) at the event in Madrid.
The trial is of particular interest to healthcare professionals. As one physician observed recently: “The question of how long to continue treating patients responding well on an immune checkpoint inhibitor is a question that practicing oncologists face daily.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze